Latest Data & Signals Issued
|Signal Type||Signal Value||Data|
|Score||-4.039||21 days ( 15.54 % )|
|Last Price||$2.12||-2.75 %|
|High/ Low||$2.11 - $2.24||6.64%|
|Chg 7 Days||0.474 %||$2.11 $2.12|
|Chg 30 Days||-19.70 %||$2.64 $2.12|
|Chg 12 mos||-90.51 %||$22.34 $2.12|
|Trend - 3 mos||-60.37 %||Width: 36.36 %|
|Trend - 12 mos||-73.75 %||Width: 284.80 %|
|Pred. range - 3 mos||$0.619 - $0.84||-70.82 % - -60.21 %|
|Pred. range - 12 mos||N/A - $1.76||-100.00 % - -17.09 %|
|Short mv avg 3 mos||Buy||2023-09-27 - 3 days|
|Long mv avg 3 mos||Sell||0000-00-00 - N/A days|
|Short/Long mv avg 3 mos||Sell||0000-00-00 - N/A days|
|Short mv avg 12 mos||Sell||2023-06-21 - 71 days|
|Long mv avg 12 mos||Sell||2023-06-21 - 71 days|
|Short/Long mv avg 12 mos||Sell||0000-00-00 - N/A days|
|Pivot Short||Buy||2023-09-26 - 4 days|
|Bollinger||Buy||2023-09-15 - 11 days|
|MACD||Sell||No Dates Stored For This Signal|
Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.
Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.
Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).
Moving Average (7d)
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul... FATE Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.